Thrombotic Thrombocytopenic Purpura (TTP)

Thrombotic Thrombocytopenic Purpura (TTP) is a rare blood disorder that affects the body's ability to control blood clotting. It involves the formation of tiny clots in small blood vessels throughout the body, which can block blood flow and damage organs like the brain, kidneys, and heart. This condition primarily affects the blood and circulatory system. People with TTP often experience symptoms such as low platelet counts, which can cause easy bruising and bleeding, and anemia due to destruction of red blood cells. The clots can lead to serious problems like confusion, fever, and kidney failure. Early recognition and treatment are critical to prevent life-threatening complications. The disorder is caused by a problem with a protein that normally helps regulate clotting.

Thrombotic Thrombocytopenic Purpura (TTP) is a life-threatening microangiopathic hemolytic anemia characterized by widespread formation of platelet-rich thrombi in the microvasculature. The core pathology involves a severe deficiency of the metalloprotease ADAMTS13, which normally cleaves ultra-large von Willebrand factor multimers, preventing excessive platelet aggregation. This deficiency is most commonly acquired due to autoantibodies against ADAMTS13, but can also be hereditary due to mutations in the ADAMTS13 gene. The resulting microthrombi cause thrombocytopenia, microangiopathic hemolytic anemia, and ischemic organ damage, especially affecting the brain and kidneys. Clinically, TTP presents with a pentad of fever, neurologic symptoms, renal dysfunction, thrombocytopenia, and hemolytic anemia, although not all features are always present. Prompt diagnosis and treatment are essential due to the high mortality risk without intervention.